Throughout the last three months, 5 analysts have evaluated Thermo Fisher Scientific TMO, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 3 | 1 | 0 | 0 |
| Last 30D | 0 | 2 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $654.0, with a high estimate of $680.00 and a low estimate of $605.00. Experiencing a 1.36% decline, the current average is now lower than the previous average price target of $663.00.
Interpreting Analyst Ratings: A Closer Look
A clear picture of Thermo Fisher Scientific's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brandon Couillard | Wells Fargo | Raises | Overweight | $680.00 | $660.00 |
| Tejas Savant | Morgan Stanley | Raises | Overweight | $678.00 | $647.00 |
| Tejas Savant | Morgan Stanley | Lowers | Overweight | $647.00 | $670.00 |
| Sung Ji Nam | Scotiabank | Announces | Sector Perform | $605.00 | - |
| Derik De Bruin | B of A Securities | Lowers | Buy | $660.00 | $675.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Thermo Fisher Scientific. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Thermo Fisher Scientific compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Thermo Fisher Scientific's stock. This analysis reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Thermo Fisher Scientific's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Thermo Fisher Scientific analyst ratings.
Discovering Thermo Fisher Scientific: A Closer Look
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
Thermo Fisher Scientific: A Financial Overview
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Thermo Fisher Scientific's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.23% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Thermo Fisher Scientific's net margin is impressive, surpassing industry averages. With a net margin of 15.38%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Thermo Fisher Scientific's ROE excels beyond industry benchmarks, reaching 3.38%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Thermo Fisher Scientific's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.64% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Thermo Fisher Scientific's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.72.
How Are Analyst Ratings Determined?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
